TRANSLATIONAL PARKINSON’S DISEASE RESEARCH

Patrik Brundin Laboratory

Research in Patrik Brundin’s laboratory focuses on pathogenetic mechanisms and pharmacological treatment in cell and animal models of Parkinson’s disease. The group’s mission is to understand neurodegenerative diseases and develop new therapies that are of benefit to patients and their caregivers.

Facebook

Help us welcome our new board member, Patrik Brundin, M.D., Ph.D. He is director of the Center for Neurodegenerative Science and the inaugural holder of the Jay Van Andel Endowed Chair in Parkinson’s Research at Van Andel Institute in Grand Rapids, Michigan, USA. He is an internationally renowned expert in the field of Parkinson’s and neurodegenerative disease research whose career spans more than 35 years, including key involvement in some of the first clinical neural transplantation trials. He obtained his M.D. (1992) and Ph.D. (1988) at Lund University in Sweden where he served as a Professor of Neuroscience from 2000 to 2014. He has published more than 300 papers, coordinated several multidisciplinary, international research networks specializing in Parkinson’s research and was identified as a ISI Highly Cited Scientist in his area. His main current research interests are related to alpha-synuclein acting in a prion-like fashion; animal models of Parkinson’s disease; drug repurposing; and development of disease-modifying therapies in Parkinson's disease. In addition to leading his lab at the Institute, he is co-editor-in-chief of the Journal of Parkinson’s Disease, a member of the World Parkinson Coalition’s Board of Directors and chair of the Linked Clinical Trials committee. You can read more about our other illustrious board members here: www.worldpdcoalition.org/Directors

“We hope this will be a watershed moment for millions of people living with Parkinson’s disease,” says Dr. Patrik Brundin. “All of our research in Parkinson’s models suggests this drug could potentially slow the disease’s progression in people as well.”
Read our latest news here: www.vai.org/featured-news/

People with Parkinson's have clumps of the protein alpha-synuclein in brain cells, which researchers believe may lead to disease symptoms and progression. Our panelists discuss clinical trials of therapies to prevent or treat those clumps and protect cells, as well as what we know about this key pro...